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Abstract
Thalidomide possesses both anti-inflammatory and anti-angiogenic properties. This study investigates its potential
application in islet transplantation with a xenogenic transplantation model. Transplantation was performed using C57Bl/6
mice and NMRI nu/nu mice as recipients of porcine islets. Moreover, islet graft vasculature and inflammation were
investigated to identify the mechanisms of thalidomide action. In the immunocompetent environment of C57Bl/6 mice, a
fast graft rejection was observed. The group treated with thalidomide 200 mg/kg BW per day achieved and maintained
euglycemia in the complete observation period for 42 days. The treated mice had more functional islet graft mass with less
leukocyte infiltration. The pro-inflammatory TNF-a and VEGF content in islet grafted kidneys was significantly lowered by
the treatment. By comparison, thalidomide was not effective in improving graft survival in immunocompromised nude
mice. It strongly inhibited the VEGF and TNF-a-induced endothelial proliferation of isolated pig islets in a dose dependent
manner. The magnitude of thalidomide’s inhibitory effect was nearly identical to the effect of VEGF- receptor 2 inhibitor
SU416 and anti-TNF-receptor 1 neutralizing antibody, and was reversed by sphingosine-1-phosphate. In conclusion, the
anti-inflammatory effect of thalidomide improved islet graft survival and function in a transplantation model with a
maximum immune barrier.
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Introduction
Islet transplantation represents a potential cure for type 1
diabetes. Great improvements have been achieved since the
introduction of the Edmonton protocol [1,2]. However, two or
more donor pancreata are routinely needed for one recipient, thus
representing a major obstacle for the widespread application of
islet transplantation [1,3,4]. Conversely, it is generally believed
that only a small fraction of the transplanted islets successfully
engraft [5], indicating that more effort is needed to improve the
current protocol. Both non-immune and innate immunological
factors have been indicated in the primary non-function and
failure of islet graft [6,7]. In islet xenotransplantation, which could
potentially resolve the extreme shortage of human donor
pancreata by using the pig as the source of islets, even more
severe inflammation and early graft loss were observed
[8,9,10,11].
Among the different mechanisms and molecules that are
implicated in early graft dysfunction and death, tumor-necrosis
factor alpha (TNF-a) is one of the most widely studied [12]. TNF-
a is a key regulator of systemic inflammation and a stimulator of
the acute phase reaction. Several studies have demonstrated that
the plasma level of TNF-a is increased by hyperglycemia and
diabetes [13,14,15]. In islet transplantation, islet-toxic TNF-a has
been shown to be produced locally at the graft site by recipient
macrophages, as well as by resident macrophages within the islet
itself [16,17]. Inhibition of TNF-a production is shown to improve
islet survival and functions [17]. On the other hand, although
TNF-a has been validated as a drug target with Remicade and
Enbrel available as prescription medications, both are large
macromolecules and require injection which limit their clinical
applications.
Thalidomide is a TNF-a inhibitor that has anti-angiogenic,
immunomodulatory and anti-inflammatory effects [18,19]. It was
first introduced in the 1950s as a sedative and quickly withdrawn
in 1961 because of its teratogenic effects. However, it was
reintroduced in 1997 as an immunomodulator and is now
successfully used in the treatment of multiple myeloma, leprosy
and various autoimmune diseases [20]. Thalidomide has potent
anti-inflammatory activity. It inhibits the production of TNF-a in
monocytes and macrophages by increasing the rate of TNF-a
mRNA degradation [21,22]. In addition, thalidomide is capable of
blocking NF-kB activation via a mechanism that involves
suppression of IkB kinase activity in T lymphocytes [23].
Furthermore, thalidomide treatment was shown to down-regulate
the increased expression of P-selectin and intercellular adhesion
molecule (ICAM-1) in injured endothelium, thus reducing
neutrophil recruitment [24].
Given the unique immunomodulatory property of thalidomide,
this study was designed to evaluate its therapeutic potential on islet
graft survival, functions and revascularization using an islet
xenotransplantation model. We hypothesized that the anti-
inflammatory effect of thalidomide, especially the inhibition of
TNF-a production, could protect the islet graft from the
destructive post-transplantation inflammatory events and improve
the transplantation outcome. We investigated the effects of
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leukocyte infiltration and TNF-a content in the graft, graft surface
blood flow and vascular density in the recipients after porcine islets
were transplanted into C57Bl/6 mice. The effect of thalidomide
on VEGF and TNF-a-induced angiogenesis was studied using an
ex vivo pig islet sprout assay. In order to exclude its anti-
inflammatory effect, the influence of thalidomide’s anti-angiogenic
effect on islet xenograft survival and functions was studied using
the immunocompromised NMRI nu/nu mice as recipients.
Materials and Methods
Pig islet isolation
Pig islets were isolated at the Islet Isolation Facility of
Medizinische Klinik und Poliklinik III am Universita ¨tsklinikum
Gieben using previously described techniques of collagenase
digestion and Ficoll purification [25,26]. After isolation, the
quality of islet isolation was evaluated by Trypan Blue exclusion,
dithizone staining and glucose-stimulated insulin secretion to
check viability, purity and function. The purity varied from 95–
100% and viability was more than 95% for subsequent
experiments. The islets were cultivated in a humidified air
atmosphere after isolation until use within 5 days.
Animal research was approved by Regional Commission
Giessen, Germany under the code number GI20/11-Nr.15/
2006. Animal husbandry was performed according to the German
Animal Welfare Law as published in the latest version under
http://bundesrecht.juris.de/tierschg.
Islet transplantation
Before transplantation, diabetes was induced in the recipients by
a single injection of 200 mg/kg streptozotocin (Sigma-Aldrich)
intravenously into the tail vein, and blood glucose levels were
determined by Glucometer Elite (Bayer). Mice with a blood
glucose value of more than 300 mg/dL for at least two consecutive
days were used as transplant recipients.
Recipients were anaesthetized with 2.5% avertine (200 mL/
100 g, Sigma), and the kidney was assessed by an incision of the
left flank. 3,000 IEQ of porcine islets were transplanted beneath
the kidney capsule of diabetic mice. The wound was closed in two
layers with absorbable sutures. Blood-glucose levels were analyzed
during the postoperative days.
Thalidomide, at a dose of 200 mg per kg body weight [24], was
dissolved in dimethylsulfoxide (DMSO) and a daily intraperitoneal
injection was given to mice in the treated groups starting at three
days prior to transplantation and continuing through to the end of
the experiments. Preliminary experiments indicated that the
vehicle, DMSO, was not toxic to the animals.
The kidney, bearing islet grafts, was recovered from the body
for histological analysis or protein extraction after 14 days in the
C57Bl/6 control group (vehicle only) and one thalidomide-treated
C57BL/6 group, and after 42 days in the other groups. Three days
after explantation of the graft, the blood-glucose levels were
analyzed to verify the recurrence of diabetes.
Measurements of blood flow in transplanted islets
The blood flow of the islet graft was measured as previously
described [27]. Briefly, the blood perfusion of the islet graft and
the adjacent renal cortex was measured by laser-Doppler flow
detection (PF 4001–2, Perimed, Stockholm, Sweden) with a needle
probe (411 mm tip; outside diameter, 0.45 mm). The flow probe
was positioned perpendicular to the immobilized tissue surface by
the use of a micromanipulator, and care was taken not to cause
any compression of the tissue. The blood flow was calculated as
the percentage of the graft flow rate to kidney surface flow rate.
Protein analysis of the islet grafts
For protein extraction the frozen grafts were thawed and lyzed
for 30 min by 10% dithiothreitol 10 mM, 1% protease inhibitor
cocktail, and 89% buffer AM1 (Active Motif, Rixensart, Belgium).
The supernatant was collected after two centrifugation steps at
3,000 g for 10 min. In the resulting lysate protein concentrations
were determined using specific mouse immunoassays for insulin
(DRG, Marburg, Germany), VEGF, or TNF-a (R&D systems,
Abingdon, UK) according to the manufacturers’ instructions.
Myeloperoxidase (MPO) assay
Grafted kidneys were homogenized in 1 ml PBS at 4uC using a
Polytron homogenizer (five bursts of 10 s each at maximum
speed). 250 ml of the homogenate was added to 250 ml
hexadecyltrimethylammonium bromide, vortexed, and incubated
for 2 min. After centrifugation, the supernatant was collected and
assayed for MPO activity by adding 55 ml tetramethylbenzidine
substrate to 30 ml of the supernatant. The absorbance was read at
630 nm at intervals of 30 s for 2 min.
Immunohistology and Measurement of Vascular Density
Whole graft-containing kidneys were embedded in Paraplast.
Each kidney block was serially sectioned (7 mm) throughout its
length. Endothelial cells (ECs) and microvessels were identified by
staining with biotinylated Bandereira simplicifolia (BS-1, Sigma) as
previously described [27,28]. Briefly, slides were pretreated with
neuraminidase type X (Sigma) and incubated with biotinylated
BS-1 at 4uC overnight. After three rinses with PBS, they were
incubated with StreptABComplex (Dako) for 30 minutes at room
temperature. Subsequently, fuchsin and 1 mM levamisole were
added and developed. Finally, the sections were counterstained
with hematoxylin, cleared and mounted. Vascular area cross
sections within grafts were counted for percentage of lectin-positive
area in 7 to 10 5000-mm
2 fields in each section with a light
microscope (magnification 2006) combined with an image
analysis system (Motic, Wetzlar, Germany). Vascular density was
expressed as percentage of vascular area to total area examined.
Islet Sprouting
Three hundred microliters of bovine fibrinogen dissolved in
Dulbecco’s PBS at 1.7 mg/ml, containing aprotinin was added to
wells of a 24-well plate. After a 24-h pre-culture period, 20–30
islets were embedded into each of the prepared wells. Thalidomide
or vehicle (DMSO) was subsequently added prior to fibrin
polymerization induced by addition of 5 ml of thrombin
(1000 U/ml). Anti-TNFR1 neutralizing antibody (clone 55R-
170, R&D systems) was also added before fibrin polymerization.
Additionally, the flk-1 (VEGFR 2) inhibitor, SU416, and the
enhancer of VEGF-induced angiogenesis, sphingosine-1-phos-
phate (S1P) (both purchased from Sigma-Aldrich) were used prior
to fibrin polymerization. Cultivation of islets was carried out in
medium containing bFGF, VEGF or TNF-a (all human
recombinant, BD Biosciences, San Jose, USA) for 48 h or time
indicated at the concentrations specified. Gels were fixed with 3%
formaldehyde and stained with crystal violet. Washed gels were
transferred onto slides and fixed with Kayser’s glycerin gelatin.
Islet vitality was tested prior to the angiogenesis assay using
Trypan Blue staining and by determination of islet morphology in
the fixed gels. Vital islets did not disperse and had a smooth shape
without cellular protrusions. Their angiogenic potential was
Thalidomide and Islet Graft
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containing at least one capillary sprout were considered to be
angiogenic. At any tested condition at least three independent
experiments were performed.
Statistics
Results are given as mean6SEM. Statistical significance was
determined using student’s t-test or one-way ANOVA with
posthoc Bonferroni’s test, as appropriate. A value of p,0.05 was
considered statistically significant.
Results
Death rate in transplanted C57Bl/6 mice reduced by
thalidomide
As shown in Figure 1A where the surviving animal numbers are
indicated above the blood glucose curve, the death rate prior to
retrieval of the graft-bearing kidney was higher in the C57Bl/6
vehicle group compared to the thalidomide treated C57Bl/6 mice
(4/11 vs 0/12). In critical situations, blood glucose values of the
surviving mice in the vehicle group dropped down dramatically
indicating that the animals were going to die. This is proved to be
true by the fact that only 1 mouse from this group survived after
removing the grafted kidney while 11 out of 12 mice in the treated
group survived.
Thalidomide improved glycemic control and islet graft
survival in C57Bl/6 mice recipients
A rapid rejection was found in the vehicle C57Bl/6 mice group
after transplantation with blood glucose values dramatically
increased (Figure 1A). All the mice became diabetic again and
36% (4/11) of them died due to severe diabetes before the retrieval
of the graft at day 14. In contrast, the thalidomide-treated mice
were restored with euglycemia for the period of observation
although the blood glucose values increased slowly following
transplantation.
Consistently, a significantly higher graft insulin content was
found in the thalidomide-treated C57Bl/6 group at day 42
compared to the vehicle group (mg insulin/mg protein:
20.6360.82 vs 3.0860.57, p,0.01; Figure 1 B), indicating that
a greater islet graft mass resulted from the treatment.
After the removal of the islet graft-bearing kidneys, all the mice
in both groups became diabetic again with six of seven survived
mice died in the vehicle group (Figure 1A), indicating that the islet
grafts were taking effect before the retrieval.
In a separate experiment, thalidomide administration without
islet transplantation did not have a noticeable impact on severity of
hyperglycemia in diabetic mice. As shown is Figure 1C, all the
mice in both groups remained diabetic during the observation
period.
Protection from leukocyte infiltration within xenograft by
thalidomide
Neutrophilic granulocytes have been shown to be the
predominant cell type infiltrating islets in vitro [29]. Therefore,
we investigated the effect of thalidomide treatment on neutrophil
infiltration by measuring the MPO activity in islet graft. Tissue
MPO activity correlates with the number of neutrophils
extravasated into the xenograft [30]. As shown in Figure 2A, we
observed decreased neutrophil influx in the kidney of C57Bl/6
mice treated with thalidomide for 42 days (MPO mU/ml: 5.060.7
vs 8.461.2, p,0.01 vs vehicle; day 42).
Reduction of TNF-a and VEGF content in xenograft by
thalidomide
Murine TNF-a and VEGF content in the grafted kidneys was
evaluated by ELISA. The TNF-a content in the grafted kidneys in
both thalidomide treated groups at day14 and day 42 was
significantly lower than in the vehicle group (Figure 2B) on the day
of graft retrieval, while there are no significant differences between
thalidomide groups at day 14 or day 42. Thalidomide treatment
also significantly reduced VEGF content in these kidneys
(Figure 2C).
Thalidomide inhibited sprout formation in pig islets
The effect of thalidomide treatment on angiogenesis of pig islets
was examined by the ex vivo sprout formation assay of islet
endothelial cells embedded within a fibrin gel. Representative
pictures of pig islet with or without sprouting activity in the assay
are shown in Figure 3A (A1 and A2 respectively). The time course
and the percentage of sprouting pig islets were studied. As shown
in Figure 3B, the tube-like structures protruding from the islets
peaked at 48 hours after cultivation. On average, 18.764.8% of
these islets formed tube-like structures protruding from the islets in
the gel in the presence of 5 ng/ml bFGF. When different doses of
thalidomide were added to the medium, islet sprout formation was
Figure 1. Effect of thalidomide treatment on glycemic control in C57Bl/6 mice. Blood glucose levels of C57Bl/6 mice with islet
transplantation (A, n=11 in vehicle control group and n=12 in thalidomide treated group) or without islet transplantation (C, n=6). In islet
transplantation groups, nephrectomy of the graft bearing kidney was performed on day 14 and day 42, in control mice or treated mice respectively,
followed by blood glucose determination 3 days later. The number of the surviving animals is indicated above the curve. Insulin content in the
grafted kidneys is shown in figure B.
rremoval of graft kidney;
11n=11;
10n=10;
7n=7;
1n=1;
**p,0.01 vs control mice.
doi:10.1371/journal.pone.0006312.g001
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demonstrated that the tubes consisted of CD–31-positive endo-
thelial cells [31].
To investigate the mechanisms of thalidomide’s effects on islet
sprouting, we examined the effect of thalidomide on VEGF or
TNF-a induced angiogenesis in this model. As shown in Figure 4A,
the addition of 50 ng/ml VEGF increased the percentage of pig
islets with sprouts from 260.52 in the vehicle control to 2660.52
(p,0.01). The effect was partially inhibited to 8.8360.48 (p,0.01
vs VEGF group) by addition of 50 mg/ml thalidomide. S1P has
been reported to antagonize thalidomide’s depletion of VEGFR2
and neuropilin in human umbilical vein endothelial cells [32]. We
found that S1P increased islet endothelial sprouting in the
presence of thalidomide (18.860.6, p,0.01 vs VEGF+thalido-
mide). In addition, thalidomide’s inhibitory effect was mimicked
by the VEGFR2 inhibitor, SU416 (11.061.0, p,0.01 vs VEGF).
Furthermore, the combination of thalidomide and SU416 did not
have an accumulative inhibitory effect (9.860.6, p,0.01 vs
VEGF, NS vs thalidomide). These results indicate that thalido-
mide’s action in islet endothelial cells was predominantly mediated
by VEGFR2.
Similarly, the addition of 50 ng/ml TNF-a increased the
percentage of pig islets with sprouts to 12.8360.54 (p,0.01 vs
vehicle, Figure 4B). Thalidomide antagonized TNF-a-induced
sprouting of islets to 7.1760.98%(p,0.01 vs TNF-a alone). In
comparison, an anti-TNFR1 neutralizing antibody [33] was more
effective than thalidomide in inhibiting TNF-a induced sprouting
(3.060.4%, p,0.01 vs TNF-a). The combination of thalidomide
and anti-TNFR1 did not have an accumulative effect (2.860.4%,
p,0.01 vs TNF-a,N Svs thalidomide). The combination of VEGF
and TNF-a potentiated the sprouting rate to 47.561.5% (p,0.01
vs VEGF or TNF-a alone).Thalidomide was capable of inhibiting
VEGF/TNF-a induced sprouting significantly to 7.3361.63
(p,0.01).
Thalidomide restrained islet graft survival and function in
NMRI nu/nu mice
In order to exclude its anti-inflammatory effect, thalidomide’s
anti-angiogenic effect on islet grafts was studied in vivo by using the
immunocompromised NMRI nu/nu mice as recipients of pig
islets. As shown in Figure 5A, diabetic nu/nu mice in the vehicle
group exhibited stable euglycemia after islet transplantation until
the removal of the graft-bearing kidney. In the thalidomide-treated
group, euglycemia was achieved but blood glucose values
increased continuously from day 12 post-transplantation with
recurrence of diabetes in 7 of 8 (87.5%) mice before the recovery
of the grafted kidneys.
Consistently, less insulin content was found in thalidomide-
treated grafted kidneys compared to those of the vehicle grafted
Figure 2. Effects of thalidomide treatment on MPO activity, TNF-a and VEGF content within the grafted kidneys. The retrieved grafted
kidneys from C57Bl/6 recipients were subjected to Myeloperoxidase (MPO) assay (A) or specific mouse immunoassay for TNF-a (B) or VEGF (C). N=6
in each assay.
**p,0.01 vs vehicle control mouse kidneys.
doi:10.1371/journal.pone.0006312.g002
Figure 3. Time curve and dose-dependency of thalidomide’s
effect on sprout formation of pig islets. After cultivation of pig
islets in medium containing 5 ng/ml bFGF and different concentration
of thalidomide, the gels were fixed at the indicated times, stained and
counted for percentage of islets with sprouts. A: Representative pictures
of pig islet in the sprouting assay with or without sprouting activity (A1
and A2, respectively). B: The time curve of islet sprouting within
72 hours after cultivation. N=3 in each time point.
Vehvehicle (DMSO);
THD 10thalidomide 10 mg/ml;
THD100thalidomide 100 mg/ml.
*p,0.05 vs
Veh;
**p,0.01 vs Veh.
doi:10.1371/journal.pone.0006312.g003
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p,0.01; Figure 5B).
Thalidomide impaired graft revascularization in NMRI nu/
nu mice
As immunocompromised, the nu/nu mice did not mount a
cellular immune response of graft rejection that was confirmed by
MPO assay and graft TNF-a ELISA. As shown in Figure 6, the
MPO activity in the grafted kidneys of nu/nu mice recipients was
very low (0.960.6 mU/ml). Thalidomide treatment had no effect
on this parameter (0.760.2 mU/ml, NS vs vehicle). The
proinflammatory TNF-a content in the graft kidneys was also
very low (10.261.2 ng/mg protein). Thalidomide treatment did
not affect this parameter either (9.761.4 ng/mg protein, NS vs
vehicle). In contrast, thalidomide treatment significantly reduced
the VEGF content in the graft kidneys (ng/mg protein: 7.761.2 in
thalidomide group vs 44.065.2 in vehicle group, p,0.01;
Figure 6C).
To directly evaluate the effects of thalidomide treatment on islet
revascularization, the blood flow on the graft surface was
measured before the grafted kidney was removed on day 42.
After blood flow measurement, grafted kidneys were retrieved
from NMRI nu/nu mice and subjected to immunohistochemical
analysis using antibodies against insulin and BS-1 lectin which
binds to the luminal surface of endothelial cells [34]. As shown in
Figure 7A, thalidomide treatment resulted in an obviously
Figure 4. Effect of thalidomide on VEGF or TNF-a induced sprout formation in pig islets. 50 ng/ml VEGF, 0.5 mM S1P, 5 mM SU5146,
50 ng/ml TNF-a,1 0mg/ml Anti-TNFR1, 50 mg/ml thalidomide, used alone or in different combinations was added to the medium in the above
mentioned pig islet sprouting model. The percentage of islets with sprouts was counted. N=6 in each condition.
*p,0.05 vs vehicle control;
**p,0.01
vs vehicle control;
ˆp,0.01 vs 50 ng/ml VEGF (A) or 50 ng/ml TNF-a (B).
doi:10.1371/journal.pone.0006312.g004
Figure 5. Effect of thalidomide treatment on glycemic control in NMRI nu/nu mice. Blood glucose levels of nu/nu mice (n=8, except
indicated) in vehicle group and thalidomide treated group. Nephrectomy of the graft bearing kidney was performed on day 42, followed by blood
glucose determination 3 days later. Insulin content in the grafted kidneys is shown in figure B.
rremoval of graft kidney;
7n=7;
6n=6;
**p,0.01 vs
vehicle control mice.
doi:10.1371/journal.pone.0006312.g005
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was revealed in the thalidomide treated NMRI nu/nu mice group
compared to the vehicle group (percentage of graft flow rate to
adjacent renal cortex: 60.663.5 vs 81.461.1, p,0.01; Figure 7B).
Consistently, a significantly lower vascular density was found in
the thalidomide treated nu/nu group versus vehicle animals
(percentage of lectin-positive area: 6.561.0 vs 16.260.1, p,0.01;
Figure 7C).
Discussion
This study showed that, together with its inhibitory effect on
islet endothelial activation, thalidomide treatment improved islet
graft survival and functions in an established xenotransplantation
model. In particular, we demonstrated that thalidomide treatment
resulted in better blood glucose profile, greater islet graft mass, less
leukocyte infiltration and less cytokine content with xenograft in
the C57Bl/6 recipient mice. Furthermore thalidomide inhibited
the islet graft revascularization as demonstrated in the NMRI nu/
nu recipient mice.
In islet transplantation, especially islet xenotransplantation, a
cascade of inflammatory reactions occur following transplantation.
There is good evidence that activation of the blood coagulation
and complement system, and infiltration of the islet graft by
neutrophilic granulocytes and macrophages occur immediately
after islet transplantation [5,29]. These infiltrating cells are directly
cytotoxic to the islet graft [35]. In addition, these cells produce
inflammatory cytokines that lead to apoptosis of islet cells, mainly
via TNF-a signaling pathways and upregulation of Fas expression
[36,37]. These pathways induce islet graft apoptosis through
activation of nuclear factor-kB (NF-kB)-regulated apoptotic genes
and activation of caspases [36,38]. A third effect of neutrophils and
macrophages is their role of antigen-presentation to T-cells. In
non-immunosuppressed recipients, islet xenografts reverse diabetes
but the majority of transplanted xenogenic islets are subjected to
acute cellular rejection mediated by CD4+ and CD8+ T cells and
macrophages [39].
Thalidomide treatment protected the islet xenograft in the
current study. A rapid graft loss was found in the control C57Bl/6
recipient mice. Shortly after islet transplantation these mice
quickly lost the grafts and became diabetic again. Thalidomide-
treated mice maintained their functioning islet graft and had much
better glucose control. Several anti-inflammatory mechanisms
have been investigated here. First, thalidomide treatment
dramatically reduced the TNF-a content in the grafted kidneys
in the C57Bl/6 mice. TNF-a is a key regulator of other
proinflammatory cytokines and of leukocyte adhesion molecules,
and is a priming activator of inflammatory cells. Since the TNF–a
pathway is one of the major pathways that lead to loss of islet
grafts, the inhibitory effect of thalidomide on TNF-a content in
islet grafted kidneys in this study may primarily explain the
decreased rate of islet graft loss.
Secondly, thalidomide treatment reduced leukocyte infiltration
of the islet graft as evidenced by reduced MPO activity. As
discussed above, neutrophils are the major effector cells that lead
to early graft loss in islet transplantation. The reduced neutrophil
infiltration by thalidomide provides additional protection to the
islet graft. This is consistent with another study in which
thalidomide reduced leukocyte recruitment and tissue damage
within the pancreas in a mouse model of acute pancreatitis [24].
Thirdly, thalidomide reduced VEGF content in the grafted
kidneys. Although VEGF is essentially required in the islet graft
revascularization process, excessive VEGF induces increased
microvascular hyper-permeability and activation of the coagula-
tion pathway. In the current study, reduced VEGF content in the
graft kidneys by thalidomide treatment is correlated with
decreased sluggish blood flow associated with the inflammatory
reaction observed in the control C57Bl/6 mice.
These three mechanisms may produce a cumulative protective
effect on transplanted tissue, as demonstrated by the facilitation of
sustaining islet graft functions in thalidomide-treated C57Bl/6
recipient mice.
In addition to its anti-inflammatory property, thalidomide also
possesses an anti-angiogenic potential. The latter was confirmed in
both an ex vivo islet sprouting model and an in vivo islet
transplantation model in the current study. In the ex vivo islet
sprout assay, thalidomide inhibited the sprout formation induced
by basic fibroblast growth factor (bFGF) in a dose-dependent
manner. TNF-a has been shown to stimulate angiogenesis directly,
and also indirectly, by enhancing the synthesis of bFGF
[40,41,42]. Here, TNF-a increased the sprout formation by 6-
fold when used alone and 23-fold when combined with VEGF.
The addition of thalidomide to the medium significantly inhibited
the increase by 44.2% and 84.8%, respectively. The magnitude of
thalidomide’s inhibitory effect on VEGF-induced sprout formation
was identical to the magnitude of the effect of the Flk-1 inhibitor,
SU416, and was reversed by the VEGF-receptor increasing S1P.
Similarly, thalidomide’s inhibitory effect on TNF-a-induced
sprout formation was comparable with the effect of the anti-
TNFR1 neutralizing antibody. The combinations of thalidomide
with SU416 or anti-TNFR1 did not produce an accumulative
inhibitory effect. These results indicate that thalidomide may act
Figure 6. Effects of thalidomide treatment on MPO activity, TNF-a and VEGF content in the grafted kidneys. The retrieved grafted
kidneys from NMRI nu/nu recipient mice were subjected to Myeloperoxidase (MPO) assay (A) or specific mouse immunoassay for TNF-a (B) or VEGF
(C). N=6 in each assay.
**p,0.01 vs vehicle control mouse kidneys.
doi:10.1371/journal.pone.0006312.g006
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angiogenesis effect. In the in vivo islet transplantation model,
thalidomide may have an additive inhibitory effect on endothelial
proliferation by reducing the TNF-a/VEGF content in the local
graft site and a direct inhibitory effect on TNF-a/VEGF-induced
angiogenesis. Although we were unable to compare the revascu-
larization process in the C57Bl/6 mice groups due to the rapid
graft loss in the control group, thalidomide demonstrated its anti-
angiogenesis effect clearly in the nu/nu mice. The treated mice
had greatly impaired islet graft revascularization, evidenced by
vascular density count and graft surface blood flow measurement,
compared to the control recipients. Since these mice are
immunocompromised nude mice and did not mount a cellular
immune response of graft rejection, we infer that the impaired islet
graft survival in these recipients resulted from the impaired graft
revascularization process.
Both anti-inflammatory and anti-angiogenic properties of
thalidomide were demonstrated in the current study. It appears
that thalidomide can exhibit different characteristics depending on
the immune barrier. In the C57Bl/6 mice groups, where rapid
graft rejection and inflammatory reactions destroyed the islet graft
shortly after transplantation, thalidomide exhibited a mainly anti-
inflammatory effect and improved islet graft survival and
functions. In the NMRI nu/nu mice, which did not mount a
cellular immune response of graft rejection, thalidomide exerted a
mainly anti-angiogenic effect.
Interestingly, thalidomide treatment seems to result in adequate
blood flow to the islet graft in the immunocompetent C57Bl/6
recipients and protected the graft from the microvascular injury
observed in the controls. Those microvessels induced by
inflammatory cytokines, such as TNF-a and excessive VEGF at
the graft site, were leaky and did not contribute to the required
Figure 7. Effects of thalidomide treatment on vascular density and graft surface blood flow in nu/nu mice. Forty-two days post-
transplantation, after the blood flow on the graft surface was measured, the grafted kidneys were retrieved and subjected to immunohistochemistry
using antibodies against Bandereira simplicifolia (BS-1) lectin. A: Representative pictures of immunostaining of islet graft (dashed line) with BS-1 (red
color) at the kidney capsule of nu/nu NMRI mice treated with vehicle (A1) or thalidomide (A2). Magnification6100 in both pictures, and6400 in the
small pictures inserted. The blood flows were calculated as the percentage of the graft flow rate to kidney surface flow rate (B, n=6). The vascular
density was quantitated as the percentage of lectin-positive area in relation to total section area (C, n=4).
**p,0.01 vs vehicle control graft.
doi:10.1371/journal.pone.0006312.g007
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effect may provide an additional protective mechanism in this case
by inhibiting islet endothelial activation.
In conclusion, we have demonstrated that in vivo administration
of thalidomide exerted beneficial effects on the overall results of
islet xenotransplantation in diabetic immunocompetent mice.
These results suggest that thalidomide could be potentially applied
in islet xenotransplantation as an immunomodulator.
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